203 related articles for article (PubMed ID: 16609064)
41. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Jabbour E; Thomas D; Kantarjian H; Zhou L; Pierce S; Cortes J; Verstovsek S
Blood; 2011 Jul; 118(4):899-902. PubMed ID: 21622644
[TBL] [Abstract][Full Text] [Related]
42. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
Berrebi A; Feldberg E; Spivak I; Shvidel L
Haematologica; 2007 Feb; 92(2):e15-6. PubMed ID: 17405746
[TBL] [Abstract][Full Text] [Related]
43. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Rosillo C; Camoriano JK
Am J Hematol; 2007 May; 82(5):400-2. PubMed ID: 17133423
[TBL] [Abstract][Full Text] [Related]
44. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
Strupp C; Fenk R; Kündgen A; Gattermann N; Haas R; Germing U
Leuk Res; 2005 Aug; 29(8):967-9. PubMed ID: 15978949
[TBL] [Abstract][Full Text] [Related]
45. Thalidomide in agnogenic and secondary myelofibrosis.
Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M
Br J Haematol; 2001 Nov; 115(2):313-5. PubMed ID: 11703326
[TBL] [Abstract][Full Text] [Related]
46. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
Raza A; Reeves JA; Feldman EJ; Dewald GW; Bennett JM; Deeg HJ; Dreisbach L; Schiffer CA; Stone RM; Greenberg PL; Curtin PT; Klimek VM; Shammo JM; Thomas D; Knight RD; Schmidt M; Wride K; Zeldis JB; List AF
Blood; 2008 Jan; 111(1):86-93. PubMed ID: 17893227
[TBL] [Abstract][Full Text] [Related]
47. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
List A; Dewald G; Bennett J; Giagounidis A; Raza A; Feldman E; Powell B; Greenberg P; Thomas D; Stone R; Reeder C; Wride K; Patin J; Schmidt M; Zeldis J; Knight R;
N Engl J Med; 2006 Oct; 355(14):1456-65. PubMed ID: 17021321
[TBL] [Abstract][Full Text] [Related]
48. The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis.
Yip SF; So CC; Chan AY; Liu HY; Wan TsK; Chan LC
Leukemia; 2006 Jun; 20(6):1165. PubMed ID: 16572200
[No Abstract] [Full Text] [Related]
49. Thalidomide treatment in myelofibrosis with myeloid metaplasia.
Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A
Br J Haematol; 2002 May; 117(2):288-96. PubMed ID: 11972510
[TBL] [Abstract][Full Text] [Related]
50. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia.
Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G
Haematologica; 2001 Jul; 86(7):772-3. PubMed ID: 11454539
[No Abstract] [Full Text] [Related]
51. Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Lancet JE; List AF; Moscinski LC
Leukemia; 2007 Mar; 21(3):586-8. PubMed ID: 17230228
[No Abstract] [Full Text] [Related]
52. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
53. Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy.
Colagrande M; Di Ianni M; Coletti G; Peris K; Fargnoli MC; Moretti L; Lapecorella M; Tabilio A
Int J Hematol; 2009 Jan; 89(1):76-79. PubMed ID: 19052692
[TBL] [Abstract][Full Text] [Related]
54. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Mesa RA; Camoriano JK; Geyer SM; Wu W; Kaufmann SH; Rivera CE; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li CY; Tefferi A
Leukemia; 2007 Sep; 21(9):1964-70. PubMed ID: 17581608
[TBL] [Abstract][Full Text] [Related]
55. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
[TBL] [Abstract][Full Text] [Related]
56. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
Mesa RA; Yao X; Cripe LD; Li CY; Litzow M; Paietta E; Rowe JM; Tefferi A; Tallman MS
Blood; 2010 Nov; 116(22):4436-8. PubMed ID: 20651074
[TBL] [Abstract][Full Text] [Related]
57. Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
Petukhova TA; Tartar DM; Mayo K; Fung MA; Tuscano J; Jagdeo J
J Drugs Dermatol; 2016 Aug; 15(8):1024-5. PubMed ID: 27538006
[TBL] [Abstract][Full Text] [Related]
58. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
Campbell PJ; Griesshammer M; Döhner K; Döhner H; Kusec R; Hasselbalch HC; Larsen TS; Pallisgaard N; Giraudier S; Le Bousse-Kerdilès MC; Desterke C; Guerton B; Dupriez B; Bordessoule D; Fenaux P; Kiladjian JJ; Viallard JF; Brière J; Harrison CN; Green AR; Reilly JT
Blood; 2006 Mar; 107(5):2098-100. PubMed ID: 16293597
[TBL] [Abstract][Full Text] [Related]
59. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Richardson PG; Schlossman RL; Weller E; Hideshima T; Mitsiades C; Davies F; LeBlanc R; Catley LP; Doss D; Kelly K; McKenney M; Mechlowicz J; Freeman A; Deocampo R; Rich R; Ryoo JJ; Chauhan D; Balinski K; Zeldis J; Anderson KC
Blood; 2002 Nov; 100(9):3063-7. PubMed ID: 12384400
[TBL] [Abstract][Full Text] [Related]
60. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
Mesa RA; Tefferi A; Li CY; Steensma DP
Leukemia; 2006 Nov; 20(11):2063-4. PubMed ID: 16990762
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
